RandM Tornado 7000 is a Disposable Vape device with airflow control and it is rechargable. It contains 14ml 0/2/3/5% nicotine salt e-juice and vape up to 7000 puffs. There are 38 flavors for you to choose. The airflow control let you choose the best spot suit yourself plus it comes with a rechargeable Type-C port at the buttom of the device, which gurantte you finish the last drop of the ejuice in the tank all the time.
RandM Tornado 7000 Disposable Device Features: RandM Tornado Vape,randm tornado 7000 Disposable Vape Device,randm tornado vape 7000,randm tornado vape uk,RandM tornado vape 7000 Disposable Shenzhen Ousida Technology Co., Ltd , https://en.osdvape.com
☑0/2/3/5% Nicotine Salt
☑14ML of E-liquid
☑7000 Puffs per Device
☑Air Flow Control
☑Type-C Recgarge
☑Battery Rechargable
☑Integrated 850mAh Battery
☑38 Flavors Available
☑10pcs in a display box
☑240pcs in a carton
Optimistic about healthy lighting? Pharmaceutical companies have a large shareholding
Tiansheng Pharmaceutical recently announced two significant foreign investment decisions on the evening of October 18. The first involved a RMB 14.6 million investment using its own funds to acquire a 20% stake in Chongqing Guangyao Optoelectronics Technology Co., Ltd. This strategic move marks Tiansheng's entry into the health lighting sector. In addition, the company signed a "Project Investment Contract" with the Weinan District Government of Chongqing, planning to establish a local limited company to build a medical consumables production project with an estimated total investment of 360 million yuan.
Founded in December 2013, Guangyao Optoelectronics has a registered capital of 30 million yuan and has been focusing on computer systems and energy-saving lighting solutions. The company is known for its groundbreaking research and development in the fields of health and energy-saving lighting, particularly in laser lighting technology. It has already filed over 20 patents related to laser lighting and plans to file more than 80 in the coming year, highlighting its strong innovation capabilities.
The Weinan Medical Consumables Production Project is located in the southern part of the Weinan Industrial Park. The site will be provided by the Weinan District Government in coordination with the Ministry of Land and Resources. The facility will primarily produce medical consumables such as infusion sets, syringes, and other essential medical products. The government has pledged full market access for all products developed and operated by Tiansheng, including pharmaceuticals, consumables, and medical equipment. These items will be included in the local medical consortium catalog, ensuring priority procurement by public medical institutions under similar conditions, without any barriers to entry.
Tiansheng Pharmaceutical stated that these investments are expected to strengthen its industrial chain, support broader business expansion, and align with its long-term industrial strategy, ultimately generating substantial economic benefits for the company.
Notably, on September 26 this year, Tiansheng also signed a "Strategic Cooperation Framework Agreement" with the Ganzhou Municipal Government in Sichuan Province. Additionally, it entered into an "Investment Contract for Tianzhou Pharmaceutical Group’s Zhangzhou Pharmaceutical and Logistics Project" with the Jixian County Government. The project will leverage the Zhangzhou National High-tech Zone's pharmaceutical industry park to develop pharmaceutical manufacturing, logistics distribution, innovation platforms, and talent exchange. With an estimated total investment of 500 million yuan and a land area of approximately 65 acres, the project will include injection production lines, oral solid preparation facilities, pharmaceutical logistics warehouses, and quality inspection centers. The construction period is set at 22 months, and once completed, the project is expected to generate an annual output value of 500 million yuan.
This series of strategic moves underscores Tiansheng Pharmaceutical's commitment to expanding its footprint in the healthcare sector and strengthening its position in the competitive pharmaceutical market.